amfAR The Foundation for AIDS Research Annual Report 2010 Making AIDS History Contents

From the Chairman and the CEO 03 amfAR in 2010: Selected Accomplishments 04

Grants, Fellowships, and Awards 06

Research Grants

TREAT Asia Awards

MSM Initiative Awards

Public Policy Awards

Message from the Treasurer and the Chair of the Finance and Budget Committee 14

Financial Highlights 15

Leadership and Advisory Committees 18

Board of Trustees

Scientific Advisory Committee

Program Advisory Council

Management Group

2 From the Chairman and the CEO As we commemorate amfAR’s 25 years in the vanguard of the global response to HIV/AIDS, we find ourselves energized by a surge of momentum and vibrancy in the field of AIDS research. We sometimes struggle to explain the nature of this sea change that has made us more optimistic than ever before about our chances of finding a cure. Here’s one way to think about it. For many years, AIDS research focused almost exclusively on trying to define the enemy—mapping out the way in which HIV invaded the human body and set about destroying the immune system. It was a little like shining a flashlight in the dark. What you’re able to see appears with great clarity. The trouble is, you’re never really sure how vast the darkness is. The research progress we’ve made in the last few years has effectively switched on the lights. Now, at last, we can see where we’re going and chart a path forward. In fact, several potential pathways are now laid out before us. What was deemed naïve and unrealistic—even unmentionable—just a few years ago is now within the realm of possibility. To capitalize on this momentum, in 2010 we launched a new research consortium for the express purpose of bringing teams of top scientists together to work collaboratively on the search for a cure. The greatest tribute we can pay to all who have dedicated their lives and their resources to our cause is to redouble our efforts to bring this epidemic to an end. With your continued partnership and generous support, we will do precisely that.

Kenneth Cole Kevin Robert Frost Chairman of the Board Chief Executive Officer

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.

3 amfAR in 2010: Selected Accomplishments

Accelerating the Search for a Cure

Placing the search for a cure for HIV/AIDS firmly at the center of its research efforts, in May 2010 amfAR launched the Research Consortium for HIV Eradication (ARCHE), a bold new grant program supporting collaborative teams of biomedical researchers exploring the barriers to and potential for eradicating HIV infection. With first-round funding of more than $1 million, ARCHE is supporting four groups of investigators who are exploring issues that are considered central to HIV eradication—work that is already starting to change the direction of AIDS research.

Improving Treatment for Children

HIV-positive children consistently face greater disadvantages than adults when it comes to antiretroviral therapy. With the aim of improving access to higher quality pediatric HIV/AIDS care in Asia, amfAR’s TREAT Asia program launched a two-year initiative to develop strategies to support lifelong care for HIV-positive children and generate clinical data that will inform pediatric treatment guidelines.

4 Harnessing the Potential of Gene Therapy Tailoring Training amfAR announced its first ever awards for cutting-edge gene The expansion of HIV/AIDS treatment throughout Asia has brought therapy research in February 2010, supporting a broad range of hope to millions living with the virus, but it has also created a host approaches to HIV prevention, treatment, and cure. These projects of challenges for HIV clinicians and researchers as they try to stay aim to subvert the process of HIV infection and eradicate the virus abreast of the latest developments in this complex and rapidly through strategies that thwart HIV directly or block its access to changing field. To address the diversity of training needs across the cells it needs to replicate. Grantees are pursuing innovative this vast region, TREAT Asia launched an innovative education approaches such as using a type of molecular scissors to lethally program in 2010 that provides training in areas such as pediatrics cut up the HIV genome; exploring a new and more efficient means research and lab capacity development tailored to the needs of of delivering gene therapy into a patient’s body; and engineering specific settings. and testing a variety of immune interventions that could be developed into a vaccine. Meeting the HIV Needs of MSM

Expanding the HIV Knowledge Base From South Africa to Ecuador and Ukraine to Vietnam, efforts to prevent and treat HIV/AIDS among men who have sex with men During 2010, amfAR-funded investigators continued to advance (MSM) in low- and middle-income countries received a substantial and expand our understanding of HIV, publishing 35 peer-reviewed boost in 2010 from amfAR’s MSM Initiative. Through the Initiative— scientific papers in prestigious journals such asNature Medicine which concentrates its efforts in countries where HIV among MSM and the Journal of the American Medical Association. is severely neglected—amfAR made 41 community awards to grassroots groups in 35 countries, bringing the number of awards Bringing a National AIDS Strategy to Life since the program’s inception in 2007 to 101. Many of the 2010 projects built on work funded by previous awards, a testament to the growing effectiveness of MSM Initiative grantees. When amfAR’s public policy office opened in 1991, the Foundation identified the creation of a U.S. national HIV/AIDS strategy as a top goal. Finally, after two decades of unrelenting advocacy by amfAR Standing Up for Human Rights and other AIDS organizations, President Obama unveiled the National HIV/AIDS Strategy in July 2010, setting specific goals for MSM in many parts of the world face increasing levels of reducing HIV incidence, increasing access to care, and addressing homophobic and transphobic rhetoric and violence, which health disparities. impede access to vital HIV prevention, treatment, and care services for marginalized populations that are often at high risk of Toppling the Travel Ban infection. During 2010, amfAR spoke out frequently, publicly, and emphatically in support of the human rights that are inextricably linked with public health and the fight against HIV/AIDS. After years of persistent advocacy by amfAR and like-minded organizations, the U.S. government finally removed the ban on HIV-positive foreign visitors and immigrants on January 4, 2010. Three days later, the arrival of an HIV-positive man from Holland heralded a new era of unimpeded travel for people living with HIV and signaled the demise of a ban that was instituted in 1987.

5 2010 Research Fellowships, Grants, And Awards

All projects listed below were supported by amfAR during the period October 1, 2009, to September 30, 2010. Grants funded during fiscal year 2010 but awarded in previous years are shown with the year of the award in parenthesis.

amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

Inflammation and HIV persistence Characterizing and targeting persistent Using approved drugs to target latent HIV Principal Investigator: Joseph McCune, M.D., Ph.D. HIV viremia Principal Investigator: Robert F. Siliciano, M.D., Ph.D. University of California, San Francisco Principal Investigator: Sarah Palmer, Ph.D. Johns Hopkins University San Francisco, CA Swedish Institute for Infectious Disease Control, Baltimore, MD $360,000 Karolinska Institute $360,000 Solna, Sweden Collaborating Investigator: Steven Deeks, M.D. $360,000 Collaborating Investigator: Janice E. Clements, University of California, San Francisco Ph.D. San Francisco, CA Collaborating Investigator: Frederick Hecht, M.D. Johns Hopkins University University of California, San Francisco Baltimore, MD San Francisco, CA Quantitating virus in patients receiving either non-ablative or total ablative treatment Principal Investigator: John Zaia, M.D. Beckman Research Institute of City of Hope Duarte, CA $120,000

MATHILDE KRIM FELLOWS IN BASIC BIOMEDICAL RESEARCH

Pursuing HIV Eradication Studies of HIV-1 latency and reactivation using a Macrophage-T cell interactions in formation of the Novel post-transcriptional mechanisms of HIV-1 novel ex-vivo model HIV-1 reservoir latency and reactivation Alberto Bosque, Ph.D. Fedde Groot, Ph.D. Kara Lassen, Ph.D. University of Utah University of Oxford The J. David Gladstone Institutes Salt Lake City, UT Oxford, United Kingdom San Francisco, CA $125,000 (2009) $124,782 (2009) $102,340 (2008)

Optimizing Treatment CCR5 heterogeneity and mechanism of viral Mechanisms of Vpx and Vpr targeted restriction Morphogenesis and storage of HIV-1 particles resistance to CCR5 inhibitors factors Nolwenn Jouvenet, Ph.D. Reem Berro, Ph.D. Thomas Gramberg, Ph.D. Aaron Diamond AIDS Research Center Weill Medical College of Cornell University New York University School of Medicine New York, NY New York, NY New York, NY $125,000 (2008) $125,000 $125,000 Ultrapotent inhibitors of wild-type and multi-drug Contribution of E3 ubiquitin ligase activity to HIV-1 Characterization of transportin-SR2 mediated resistant HIV restriction by TRIM5 nuclear import of HIV Bruno Marchand, Ph.D. Felipe Diaz-Griffero, Ph.D. Jan De Rijck, Ph.D. University of Missouri-Columbia Albert Einstein College of Medicine of Yeshiva Katholieke Universiteit Leuven Columbia, MO University Leuven, Belgium $125,000 (2008) Bronx, NY $125,000 (2009) $80,000 (Phase II Funding) Maintenance of drug resistance mutations and Biophysical and structural studies of the HIV HIV-1 evolutionary adaptation Structural mechanisms for nuclear export of HIV-1 integrase DNA complex Morgane Rolland, Ph.D. REV by CRM1 Kushol Gupta, Ph.D. University of Washington Xiuhua Dong, M.D., Ph.D. University of Pennsylvania School of Medicine Seattle, WA University of Texas Southwestern Medical Center Philadelphia, PA $125,000 (2008) at Dallas $125,000 (2008) Dallas, TX $125,000

Preventing HIV Transmission Evaluation of the immunonicity of “evolved” stable Generation of stable HIV-1 Env trimers through A chemical campaign to identify HIV-1 entry HIV-1 Env trimers virus evolution inhibitors Rogier Sanders, Ph.D. Rogier Sanders, Ph.D. Navid Madani, Ph.D. Academic Medical Center of the University of Academic Medical Center, University of Dana-Farber Cancer Instiute, Harvard Medical Amsterdam Amsterdam School Amsterdam, Netherlands Amsterdam, Netherlands Boston, MA $62,675 (Phase II) $125,000 (2008) (Phase I) $125,000 (2009)

6 RESEARCH FELLOWSHIPS

Pursuing Eradication Direct injectable cell targeting vectors for Engineer pluripotent stem cell derived NK cells to In vivo modeling of HIV persistence and its improved HIV gene therapy kill HIV infection eradication Joseph Anderson, Ph.D. Zhenya Ni, Ph.D. Paul Denton, Ph.D. University of California, Davis University of Minnesota University of North Carolina at Chapel Hill Davis, CA Minneapolis, MN Chapel Hill, NC $125,000 $125,000 $63,483 (transfer) (2008) Creation of a synergistic immune response to HIV In vivo modeling of HIV persistence and its Viral persistance in the MGT of RT-SHIV infected by gene therapy eradication macaques on HAART Alejandro Balazs, Ph.D. Paul Denton, Ph.D. Miranda Xhilaga, Ph.D. California Institute of Technology University of Texas Southwestern Medical Center Monash University Pasadena, CA at Dallas Melbourne, Australia $125,000 Dallas, TX $125,000 (2007) $125,000 (2008)

Optimizing Treatment Identifying cellular cofactors of rhesus monkey Cellular factors required for HIV cell-to-cell What they’re not telling me: Veterans, trust, TRIM5-alpha transmission and HIV management Devin Christensen, Ph.D. Jing Jin, Ph.D. Kristin Mattocks, Ph.D. University of Utah Yale University School of Medicine Yale University Salt Lake City, UT New Haven, CT New Haven, CT $125,000 (2009) $125,000 (2009) $108,480 (2008) Impulsivity, drug abuse, and HIV medication adherence: An fMRI study Christina Meade, Ph.D. Duke University Durham, NC $49,533 (2007)

Preventing HIV Transmission Cell phone use among MSM in stigmatized The role of mental health issues in HIV acquisition Anal intercourse, STIs, and HIV among STD settings: Implications for HIV among female drug users clinic clients Joyce Nyoni, Ph.D. Gail Gilchrist, Ph.D. Marjan Javanbakht, Ph.D. University of Dar es Salaam L’Institut Municipal d’Investigacio Medica University of California, Los Angeles Dar es Salaam, Tanzania Barcelona, Spain Los Angeles, CA $114,110 (2009) $124,915 (2008) $112,193 (2007)

RESEARCH GRANTS

Pursuing HIV Eradication Combination of CCR5∆32 and siRNAs In vivo virus persistence during suppressive Treatment intensification: Effects on persistent targeting HIV therapy in the RT-SHIV model viremia Lung-Ji Chang, Ph.D. Zandrea Ambrose, Ph.D. Sarah Palmer, Ph.D. University of Florida University of Pittsburgh Swedish Institute for Infectious Disease Control, Gainesville, FL Pittsburgh, PA Karolinska Institute $120,000 $120,000 (2008) Solna, Sweden $120,000 (2008) Engineering and characterization of HIV-specific Animal model for controlled SIV infection homing endonucleases Cristian Apetrei, M.D., Ph.D. IL-7 and antigen driven proliferation generate Keith Jerome, M.D., Ph.D. Tulane University distinct HIV reservoirs University of Washington New Orleans, LA Rafick-Pierre Sékaly, Ph.D. Seattle, WA $119,687 (2008) Université de Montréal, Centre de Recherche du $120,000 CHUM Autophagy and intracellular HIV in macrophages Montréal, Canada Using homologous recombination to stack genetic Vojo Deretic, Ph.D. $106,164 (2008) resistance to HIV infection University of New Mexico Health Sciences Center Matthew Porteus, M.D., Ph.D. Albuquerque, NM Quantification of HIV provirus: Integration and University of Texas Southwestern Medical Center $120,000 (2008) replication competence Dallas, TX Celsa Spina, Ph.D. $120,000 HDAC inhibition and chromatin remodeling to Veterans Medical Research Foundation disrupt proviral latency San Diego, CA David Margolis, M.D. $117,600 (2008) University of North Carolina at Chapel Hill Chapel Hill, NC $120,000 (2008) 7 Optimizing Treatment Evaluating healthy living curriculum for HIV- The role of PIP2 as a cofactor for HIV-1 assembly HIV conspiracy beliefs among MSM in inner-city infected youth at the plasma membrane slum area of Johannesburg A New York State HIV Research Centers Akira Ono, Ph.D. Waimar Tun, Ph.D. Consortium Grant University of Michigan Population Council Susan Abramowitz, Ph.D. Ann Arbor, MI New York, NY New York University School of Medicine $120,000 (2009) $119,977 (2008) New York, NY $32,999 Target of Vpr/Vpx Restriction CDC HIV testing guidelines: Unresolved ethical Lee Ratner, M.D., Ph.D. concerns Effectiveness of a collaborative model of HIV Washington University School of Medicine Roland Merchant, M.D., Sc.D. primary care in the Bronx St. Louis, MO Rhode Island Hospital A New York State HIV Research Centers $120,000 (2009) Providence, RI Consortium Grant $120,000 (2007) Carolyn Chu, M.D. An evolutionary approach to identifying robust Montefiore Medical Center antiretroviral drug targets The impact of stigma on access to HIV treatment Bronx, NY Sara Sawyer, Ph.D. and care $33,000 University of Texas at Austin Jennifer Sayles, M.D. Austin, TX University of California, Los Angeles, David Geffen High-throughput screens for inhibitors of Vif- $120,000 (2009) School of Medicine APOBEC3G interaction Los Angeles, CA Dana Gabuzda, M.D. Mistrust of evidence-based medicine affects $120,000 (2007) Dana-Farber Cancer Institute, Inc. health outcomes of Latinos Boston, MA Scott Rhodes, Ph.D. Immunologic benefits of CCR5 inhibitor $120,000 (2009) Wake Forest University Health Sciences intensification Winston-Salem, NC Robert Shafer, M.D. $120,000 (2008) Palo Alto Veterans Administration Medical Center and Stanford University Palo Alto, CA $107,644 (2007)

Preventing HIV Transmission A pilot study of a text messaging-enhanced POL Neurocognitive factors in the relationship between Minority stress, social support, and sexual risk in HIV intervention program drug use and risky sex South African MSM Hongjie Liu, Ph.D. Sarit Golub, Ph.D. Theodorus Sandfort, Ph.D. Virginia Commonwealth University Research Foundation of the City of New York Research Foundation for Mental Hygiene, Inc. Richmond, VA Flushing, NY New York, NY $119,894 (2009) $120,000 (2008) $119,836 (2008) Assessing internet users’ preferences for HIV prevention efficacy beliefs about male Epithelial injury and HIV penetration after structural and network interventions circumcision in South Africa simulated ejaculation Willi McFarland, M.D. Joanne Mantell, Ph.D. Craig Hendrix, M.D. San Francisco Department of Health HIV Center for Clinical and Behavioral Studies Johns Hopkins University School of Medicine San Francisco, CA at the New York State Psychiatric Institute and Baltimore, MD $102,421 (2009) Columbia University $120,000 (2007) New York, NY $119,906 (2008)

RESEARCH AWARDS Optimizing Treatment HIV/AIDS and aging: Emerging issues in research, International consensus meeting on AIDS-related care, treatment and prevention CMV retinitis Judith Auerbach, Ph.D. Gary N. Holland, M.D. San Francisco AIDS Foundation University of California, Los Angeles San Francisco, CA Los Angeles, CA $5,500 $25,000

8 TREAT Asia Grants and Awards

All projects listed below were supported by amfAR during the period October 1, 2009, to September 30, 2010. Grants funded during fiscal year 2010 but awarded in previous years are shown with the year of the award in parentheses.

ASIA PACIFIC HIV OBSERVATIONAL DATABASE (APHOD) Matthew G. Law, Ph.D. University of New South Wales Coogee, Australia $332,278 (Year 5) $279,293 (2009–Year 4)

TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD) Huy Bui, Ph.D., M.D. Tuti Parwati Merati, M.D. Evy Yunihastuti, M.D. National Hospital of Tropical Diseases Udayana University School of Medicine Cipto Mangunkusumo General Hospital Hanoi, Vietnam Denpasar, Indonesia Jakarta Pusat, Indonesia $15,000 (Year 5) $15,000 (Year 5) $15,000 (Year 5) $15,000 (2009–Year 4) $15,000 (2009–Year 4) Yi-Ming Chen, M.D., Sc.D. $5,600 (2009–Tuberculosis Expansion of Work– $12,800 (2009–Tuberculosis Expansion of Work– National Yang-Ming University Year 4) Year 4) Taipei, China $15,000 (Year 5) Shinichi Oka, M.D. Fujie Zhang, M.D. $15,000 (2009–Year 4) National Center for Global Health and Medicine Beijing Ditan Hospital $1,920 (2009–Tuberculosis Expansion of Work– Shinjuke, Japan Beijing, China Year 4) $15,000 (Year 5) $15,000 (Year 5) $15,000 (2009–Year 4) $15,000 (2009–Year 4) Jun Yong Choi, M.D., Ph.D. $880 (2009–Tuberculosis Expansion of Work–Year 4) $1,200 (2009–Tuberculosis Expansion of Work– Yonsei University College of Medicine Year 4) Seoul, South Korea Praphan Phanuphak, M.D., Ph.D. $15,000 (Year 5) HIV-NAT/Thai Red Cross AIDS Research Center Identifying biomarkers of anal intraepithelial $15,000 (2009–Year 4) Bangkok, Thailand neoplasia in Thai MSM $1,280 (2009–Tuberculosis Expansion of Work–Year 4) $15,000 (Year 5) Jintanat Ananworanich, M.D., and Nittaya $15,000 (2009–Year 4) Phanuphak, M.D. Rossana Ditangco, M.D. $2,880 (2009–Tuberculosis Expansion of Work– HIV-NAT/Thai Red Cross AIDS Research Center Asian Foundation for Tropical Medicine, Inc. Year 4) Bangkok, Thailand Muntinlupa City, Philippines $92,000 (Year 2) $15,000 (Year 5) Sanjay Pujari, M.D. $52,000 (Supplemental Funding to Year 1) $15,000 (2009–Year 4) Institute of Infectious Diseases $60,000 (2009 Year 1) $6,720 (2009–Tuberculosis Expansion of Work– Pune, India Year 4) $15,000 (Year 5) International collaboration for testing discordant $15,000 (2009–Year 4) subtypes Adeeba Kamarulzaman, F.R.A.C.P. $3,280 (2009–Tuberculosis Expansion of Work– Yi-Ming Chen, M.D., Sc.D. University of Malaya Year 4) National Yang-Ming University Kuala Lumpur, Malaysia Taipei, China $15,000 (Year 5) Thira Sirisanthana, M.D. $20,000 $15,000 (2009–Year 4) Chiang Mai University $960 (2009–Tuberculosis Expansion of Work–Year 4) Chiang Mai, Thailand Clinical epidemiology of cancer among PLHA $15,000 (Year 5) in Taiwan Nagalingeswaran Kumarasamy, M.D., M.B.B.S, Ph.D. $15,000 (2009–Year 4) Yi-Ming Chen, M.D., Sc.D. YRG Centre for AIDS Research and Education, VHS $4,880 (2009–Tuberculosis Expansion of Work– National Yang-Ming University Chennai, India Year 4) Taipei, China $15,000 (Year 5) $50,000 (Year 3) $15,000 (2009–Year 4) Somnuek Sungkanuparph, M.D. $70,000 (2009—Year 2) $12,720 (2009–Tuberculosis Expansion of Work–Year 4) Sasisopin Kiertiburanakul, M.D. (Year 5) Ramathibodi Hospital, Mahidol University Multidisciplinary services to enhance HIV testing Christopher Lee, M.B.B.S., M.R.C.P. Bangkok, Thailand and linkage to care among MSM Sungai Buloh Hospital $15,000 (Year 5) Praphan Phanuphak, M.D., Ph.D. Sungai Buloh, Malaysia $15,000 (2009–Year 4) HIV-NAT/Thai Red Cross AIDS Research Center $15,000 (Year 5) $3,200 (2009–Tuberculosis Expansion of Work– Bangkok, Thailand $15,000 (2009–Year 4) Year 4) $235,040 $1,920 (2009–Tuberculosis Expansion of Work–Year 4) Pham Thuy, M.D. Glomerular filtration rate estimation in HIV- Patrick Li, M.B.B.S. Bach Mai Hospital infected Thai patients Queen Elizabeth Hospital Hanoi, Vietnam Praphan Phanuphak, M.D., Ph.D. Hong Kong SAR, China $15,000 (Year 5) HIV-NAT/Thai Red Cross AIDS Research Center $15,000 (Year 5) Bangkok, Thailand $15,000 (2009–Year 4) Saphonn Vonthanak, M.D., Ph.D. $20,000 $800 (2009–Tuberculosis Expansion of Work–Year 4) National Center for HIV/AIDS, Dermatology and STDs Determinants of HIV disease progression Poh Lian Lim, M.D., M.P.H. Phnom Penh, Cambodia and treatment outcomes among MSM in the Tan Tock Seng Hospital $15,000 (Year 5) Philippines Singapore $15,000 (2009–Year 4) Rossana Ditangco, M.D. $15,000 (Year 5) $7,600 (2009–Tuberculosis Expansion of Work– Asian Foundation for Tropical Medicine, Inc. $15,000 (2009–Year 4) Year 4) Muntinlupa City, Philippines $640 (2009–Tuberculosis Expansion of Work–Year 4) $20,000

9 AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD) Debra Allen, M.B.Ch.B., Dip Med. Eva Jackson, M.D. Darren Russell, M.D. Northern Sydney Central Coast Area Health Blue Mountains Sexual Health and HIV Clinic Cairns Sexual Health Service Services Katoomba, Australia Cairns, Australia Holden Street Clinic $1,575 (Year 5) $6,000 (Year 5) Gosford, Australia $1,725 (2009–Year 4) $7,500 (2009–Year 4) $1,275 (Year 5) $1,200 (2009–Year 4) Eva Jackson, M.D. David Smith Nepean Hospital Sexual Health and AIDS Services Katherine Brown, M.D. Sydney, Australia Lismore, Australia South East Sydney Illawarra Area Health Service $1,350 (Year 5) $6,375 (Year 5) Warrawong, Australia $1,350 (2009–Year 4) $6,000 (2009–Year 4) $1,500 (Year 5) $1,725 (2009–Year 4) Mark Kelly, M.B.B.S. David Sowden, M.B.B.S. Prince Charles Hospital, AIDS Medical Unit Nambour General Hospital Andrew Carr, M.D. Brisbane, Australia Nambour, Australia St. Vincent’s Hospital Sydney $6,300 (Year 5) $7,500 (Year 5) Darlinghurst, Australia $7,350 (2009–Year 4) $7,500 (2009–Year 4) $7,200 (Year 5) $7,500 (2009–Year 4) Anuja Kulatunga Sharon Taylor, C.N.C. Northern Territory Department of Health Tamworth Sexual Health Service John Chuah, M.B.B.S., B.S.M.D. Casuarina, Australia Tamworth, Australia Gold Coast Health Service District $1,425 (Year 5) $825 (Year 5) Miami, Australia $1,200 (2009–Year 4) $600 (2009–Year 4) $7,500 (Year 5) $7,500 (2009–Year 4) David Nolan David Templeton, Ph.D. Royal Perth Hospital RPA Sexual Health Clinic William Donohue, M.B.B.S. Perth, Australia Camperdown, Australia University of Adelaide, Care and Prevention $7,500 (Year 5) $675 (Year 5) Program $7,500 (2009–Year 4) $600 (2009–Year 4) Adelaide, Australia $2,100 (Year 5) Tim Read Ian Woolley, M.B.B.S., F.R.A.C.P. $2,100 (2009–Year 4) Melbourne Sexual Health Centre Monash Medical Centre–Clayton Carlton, Australia Melbourne, Australia Jennifer Hoy, M.B.B.S. $5,550 (Year 5) $4,425 (Year 5) Victorian HIV Service, Alfred Hospital $6,075 (2009–Year 4) $4,825 (2009–Year 4) Melbourne, Australia $6,525 (Year 5) Norman Roth, M.B.B.S., FA.Ch.S.H.M. Lynne Wray, M.B.B.S. $6,975 (2009–Year 4) Prahran Market Clinic Pty, Ltd. Sydney Sexual Health Centre, Sydney Hospital South Yarra, Australia Sydney, Australia $7,125 (Year 5) $3,675 (Year 5) $7,500 (2009–Year 4) $3,675 (2009–Year 4)

TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TApHOD) Jintanat Ananworanich, M.D., Ph.D. Nia Kurniati, M.D. Nik Khairulddin Nik Yusoff, M.D. HIV-NAT/Thai Red Cross AIDS Research Center Cipto Mangunkusumo General Hospital Hospital Raja Perempuan Zainab II Bangkok, Thailand Jakarta, Indonesia Kota Bharu, Malaysia $10,000 (Year 4) $7,500 (Year 4) $7,500 (Year 4) $800 (Tuberculosis Expansion of Work–Year 4) $3,350 (Tuberculosis Expansion of Work–Year 4) $800 (Tuberculosis Expansion of Work–Year 4) $15,000 (2009–Year 3) $7,500 (2009–Year 3) $7,500 (2009–Year 3) Kulkanya Chokephaibulkit, M.D. Matthew G. Law, Ph.D. Kamarul Razali, M.D. Siriraj Hospital University of New South Wales Pediatric Institute, Hospital Kuala Lumpur Mahidol University Coogee, Australia Kuala Lumpur, Malaysia Bangkok, Thailand $161,157 (Year 4) $7,500 (Year 4) $10,000 (Year 4) $119,665 (2009–Year 3) $7,500 (2009-Year 3) $5,750 (Tuberculosis Expansion of Work–Year 4) $19,000 (2009–Supplemental Funding–Year 3) $20,000 (2009–Year 3) Virat Sirisanthana, M.D. Pagakrong Lumbiganon, M.D. Chiang Mai University—Research Institute for Khu Thi Khanh Dung, Ph.D., M.D. Khon Kaen University Health Sciences National Hospital of Pediatrics Khon Kaen, Thailand Chiang Mai, Thailand Hanoi, Vietnam $15,000 (Year 4) $15,000 (Year 4) $50,000 (Year 4) $8,000 (Tuberculosis Expansion of Work–Year 4) $1,000 (Tuberculosis Expansion of Work–Year 4) $15,000 (2009–Year 3) $15,000 (2009–Year 3) Rawiwan Hansudewechakul, M.D. Chiang Rai Prachanukroh Hospital Fong Siew Moy, M.D. Saphonn Vonthanak, M.D. Muang, Thailand Hospital Likas National Center for HIV/AIDS, Dermatology and $20,000 (Year 4) Kota Kinabalu, Malaysia STDs $2,650 (Tuberculosis Expansion of Work–Year 4) $7,500 (Year 4) Phnom Penh, Cambodia $20,000 (2009–Year 3) $7,500 (2009–Year 3) $20,000 (Year 4) $4,400 (Tuberculosis Expansion of Work–Year 4) Nagalingeswaran Kumarasamy, M.D., M.B.B.S, Ph.D. Revathy Nallusamy, M.B.B.S. $20,000 (2009–Year 3 Funding YRG Centre for AIDS Research and Education, VHS Penang Hospital Chennai, India Georgetown, Malaysia Prevalence of HPV and intraepithelial neoplasia $7,500 (Year 4) $2,500 (Year 4) biomarkers in adolescents $9,450 (Tuberculosis Expansion of Work–Year 4) $2,500 (2009–Year 3) Jintanat Ananworanich, M.D., Ph.D. $2,250 (Supplemental Funding–Year 4) HIV-NAT/Thai Red Cross AIDS Research Center $20,000 (2009–Year 3) Bangkok, Thailand $15,000

10 TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TApHOD) (Continued) HIV and HBV co-infection among prenatally HIV- Bone mineral density among HIV-infected Optimizing HIV treatment for children in Asia: infected adolescents in Asia adolescents Developing strategies for lifelong Care Linda Aurpibul, M.D. Kulkanya Chokephaibulkit, M.D. Praphan Phanuphak, M.D., Ph.D. Chiang Mai University Siriraj Hospital HIV-NAT/Thai Red Cross AIDS Research Center Chiang Mai, Thailand Mahidol University Bangkok, Thailand $10,000 Bangkok, Thailand $215,380 $15,000 Our Village John Tucker New Hope for Cambodian Children Killeen, Texas $37,320

TREAT ASIA QUALITY ASSURANCE SCHEME (TAQAS) Matthew G. Law, Ph.D. University of New South Wales Coogee, Australia $85,470 (Year 5) $209,787 (2009–Year 4)

TREAT ASIA STUDIES TO EVALUATE RESISTANCE (TASER) Rossana Ditangco, M.D. Matthew G. Law, Ph.D. Praphan Phanuphak, M.D., Ph.D. Asian Foundation for Tropical Medicine, Inc. University of New South Wales HIV-NAT/Thai Red Cross AIDS Research Center Muntinlupa City, Philippines Coogee, Australia Bangkok, Thailand $82,200 (Year 4) $191,236 (Year 4) $87,200 (Year 4) $66,000 (2009–Year 3) $249,713 (2009–Year 3) $66,000 (2009–Year 3) Adeeba Kamarulzaman, F.R.A.C.P. Christopher Lee, M.B.B.S., M.R.C.P. Winai Ratanasuwan, M.D. University of Malaya Sungai Buloh Hospital Siriraj Hospital, Mahidol University Kuala Lumpur, Malaysia Sungai Buloh, Malaysia Bangkok, Thailand $62,900 (Year 4) $65,400 (Year 4) $60,400 (Year 4) $66,000 (2009–Year 3) $66,000 (2009–Year 3) Thira Sirisanthana, M.D. Pacharee Kantipong, M.D. Tuti Parwati Merati, M.D. Chiang Mai University Chiang Rai Regional Hospital Udayana University School of Medicine Chiang Mai, Thailand Chiang Rai, Thailand Denpasar, Indonesia $65,400 (Year 4) $65,400 (Year 4) $62,900 (Year 4) $66,000 (2009–Year 3) $68,500 (2009–Year 3) $66,000 (2009–Year 3) Somnuek Sungkanuparph, M.D. Mahiran Mustafa, M.D. Ramathibodi Hospital, Mahidol University Hospital Raja Perempuan Zainab II Bangkok, Thailand Kota Bharu, Malaysia $105,720 (Year 4) $60,400 (Year 4) $82,000 (2009–Year 3)

OTHER RESEARCH FUNDING Randomized open-label study of second-line combination ART David Cooper, M.D. University of New South Wales Darlinghurst, Australia $125,000

PURPLE SKY NETWORK / MSM ADVOCACY PROJECTS Building environment for MSM/TG in Cambodia to Advocacy skills and HIV treatment access for Advocacy to increase resources and mobilize the access friendly health services MSM and transgender persons participation of the MSM community in the HIV Men’s Health Social Services Lao Youth Action Programme under the Lao response in Vietnam Phnom Penh, Cambodia Buddhist Fellowship Programme Institute for Social Development $10,000 Vientiane, Lao PDR Hanoi, Vietnam $10,000 $9,900

TREAT ASIA COMMUNITY PROGRAM AWARDS Tao Cai AIDS Care China Kunming, China $3,000 (Positive Commitment Award Event Support) $10,584 (Bridge Funding) $70,500 (2009–HIV/AIDS Treatment Literacy Training)

11 2010 MSM Initiative Awards and Community Awards

All projects listed below received awards from amfAR during the period October 1, 2009, to September 30, 2010. Some organizations have requested anonymity to protect the safety of their staff and clients.

MSM INITIATIVE COMMUNITY AWARDS

Africa The Access Project Extended Access Project To Support Religious Leaders in Carrying Out Alternatives-Cameroun Gay and Lesbian Coalition of Kenya, in partnership Effective HIV and AIDS Responses Targeting Douala, Cameroon with Ishtar MSM MSM and Gay, Bisexual and Transgenders $15,000 Nairobi, Kenya Through Their Faith Communities $13,800 South African Network of Religious Leaders Living Project for STI/HIV Prevention and Care for Highly with or Personally Affected by HIV & AIDS Vulnerable Populations HIV/AIDS Awareness, Advocacy, and Prevention Johannesburg, South Africa Espace Confiance, in collaboration with Sidaction, Campaign Targeting MSM: Access to Health and $15,000 Paris, France Sexual Rights in Liberia Abidjan, Côte-d’Ivoire Stop AIDS in Liberia HIV/AIDS Prevention and Treatment Information $9,000 Monrovia, Liberia Name withheld by request $15,000 Kampala, Uganda Improving Access to HIV/AIDS Treatment for $15,000 Mombasa’s MSM Community Establishment of a Drop-in Centre for MSM in PEMA Kenya Marrakesh City Sero-prevalence Study for Zambian MSM Mombasa, Kenya Association de Lutte Contre le Sida Friends of RAINKA $10,077 Marrakesh, Morocco Lusaka, Zambia $15,000 $15,750

Asia-Pacific Promoting Risk Reduction Behaviours HIV/AIDS Prevention and Support Among Expanding HIV Prevention and Outreach Among MSM Sexually Active MSM in Makassar, South Sulawesi Coverage @ Mplus+ Bandhu Social Welfare Society Province, Indonesia Mplus+ Dhaka, Bangladesh Yayasan Gaya Celebes Chiang Mai, Thailand $29,998 Makassar, South Sulawesi, Indonesia $15,000 $15,000 Legal Support to Chinese Grassroots MSM MSM Sex Workers in Hanoi: High Risks and NGOs in Their HIV-Related Activities HIV Intervention for Hidden MSM Community Barriers to HIV Prevention Chengdu Tongle Counseling & Service Center of Pakistan STD/HIV/AIDS Prevention Center Chengu, China Red Ribbon Initiative Hanoi, Vietnam $15,000 Islamabad, Pakistan $15,000 $14,975 Field-Based Oral HIV Testing and Linkage to Government Care in a High HIV Prevalence Transgender Outreach Program Region of India Action for AIDS Singapore Name withheld by request Singapore Secunderabad, India $15,980 $29,728

Caribbean Health Empowerment Through Leadership Evidence-Based, MSM-Led HIV Prevention and Bringing Hope, Building Community Development and Information Anti-Stigma Program Jamaica Forum for Lesbians, All-Sexuals and Gays United Belize Advocacy Movement Fondation Esther Boucicault Stanislas Kingston, Jamaica Belize City, Belize Saint-Marc, Haiti $15,000 $15,000 $15,000 Regional Prevention Response to HIV/AIDS Project “As I Am” Increasing Equitable Access to Prevention for Vulnerability Among MSM Populations in the Centro de Orientación e Investigación Integral MSM in Haiti Caribbean Santo Domingo, Dominican Republic SEROvie MSM: No Political Agenda $30,000 Port-au-Prince, Haiti Santa Cruz, Trinidad and Tobago $15,000 $15,000 Strengthening Community Cohesion and Building Resilience to HIV in Guyana Society Against Sexual Orientation Discrimination Georgetown, Guyana $15,000

12 Eastern Europe and Central Asia Human Rights Advocacy and HIV/AIDS PULSAR Project: Effective HIV and STI Prevention HIV Prevention and Psychosocial Support Prevention, Care, and Support for MSM Among MSM in the Siberian Region for MSM in Prisons: Scaling Up Communities in Armenia The Siberian Alternative Center Nikolaev Regional Public Youth Movement— We For Civil Equality Omsk, Russia Penitentiary Initiative Yerevan, Armenia $30,000 Nikolaev, Ukraine $14,560 $30,000 Participatory Approach to Evidence-based HIV Prevention Intervention Among MSM in Chui Planning, Establishing, and Conducting and Osh Regions of Kyrgyzstan Counseling Centers for MSM Public Fund Gender-Vector Safe Pulse of Youth Karabalta, Kyrgyzstan Belgrade, Serbia $10,000 $14,980 Prevention of HIV for MSM Through Information, HIV and Other Socially Significant Diseases Peer Counseling, and Community Mobilization Among MSM and Advocacy CSO Equal Opportunities New Life Organization Dushanbe, Tajikistan Orenburg, Russia $15,000 $15,000

Latin America Adesproc Libertad GLBT Comprehensive Care for Indigenous MSM MSM Against HIV Asociacion Civil de Desarrollo Social y Promocion Communities affected by HIV/AIDS in the Colectivo SerGay de Aguascalientes, A.C. Cultural Adesproc Libertad GLBT Northern Guajira Peninsula Region of Colombia Aguascalientes, Mexico La Paz, Bolivia Akuaipa Waimakat—Asociación para la $15,000 $7,300 Divulgación, Promoción y Defensa de los Derechos Humanos e Indígenas Intervention, Prevention and Testing for MSM Taking Care of My Life Manaure, Colombia in Puerto Vallarta Asociación Un Nuevo Camino $13,900 Vallarta Enfrenta el SIDA, A.C. La Paz, Bolivia Puerto Vallarta, Mexico $15,000 Transgender Incidence $15,000 Asociación ALFIL Adherence to Treatment, Citizenship and Quito, Ecuador Case Management: Surveying Adherence to Increasing Incomes of HIV-Positive Transvestites $15,000 Antiretroviral Treatment for HIV+ MSM in Panamá Articulação e Movimento para Travestis e Grupo Génesis Panamá Positivo Transexuais de Pernambuco We Are Healthy Panamá City, Panamá Recife, Brazil Asociación Solidaria Para Impulsar el Desarollo $12,716 $9,500 Humano (“ASPIDH—ACRO IRIS”) San Salvador, El Salvador Merchants of Illusions Project $14,993 Name withheld by request Recife, Brazil $10,000

MSM INITIATIVE AWARDS TO COLLABORATING ORGANIZATIONS Be Heard: Global Forum on MSM and HIV Pre-conference Event–IAC 2010 AIDS Project Los Angeles as secretariat for the Global Forum on MSM and HIV Los Angeles, CA $10,000

Public Policy Awards

All projects listed below were supported by amfAR during the period from October 1, 2009, to September 30, 2010.

Federal Funding for Syringe Exchange Syringe Exchange in the U.S., 2009-2010: MSM Sexual Health and HIV/STD Prevention: Don Des Jarlais, Ph.D. Assessing a Changing Landscape Post-Conference Journal Supplement Beth Israel Medical Center/Chemical Don Des Jarlais, Ph.D. Kenneth Mayer, M.D. Dependency Institute Beth Israel Medical Center/ Chemical The Fenway Institute, Fenway Community New York, NY Dependency Institute Health Center, Inc. $40,000 New York, NY Boston, MA $75,000 $10,000

13 Message from the Treasurer and the Chair of the Finance and Budget Committee

We are pleased to present the audited financial statements of amfAR, The Foundation for AIDS Research, for the fiscal year ending September 30, 2010.

Although the effects of the global economic downturn persisted throughout 2010, amfAR’s prudent financial management and the growing success of its fundraising efforts meant that the organization was able to better its budget projections and end the year with an operating surplus of $2.3 million, more than making up for last year’s $2 million deficit. With public support and revenue rising to $26.4 million, 14 percent above FY09, the Foundation has been able to move forward with long-range plans to expand its research commitments. amfAR’s operational efficiency and its effective use of donor contributions during 2010 are illustrated by two key figures. The supporting services ratio—the ratio of fundraising and management expenses to total support and revenue—was a low 23.6 percent, while the program spending ratio was a healthy 74.1 percent—meaning that 74 cents out of every dollar spent was invested directly in critical program activities. Program spending was lower in 2010 than in the previous year as a result of careful retrenchment decisions made during the height of the financial crisis in 2009. But this caution, combined with a $2.8 million increase in special events revenues, allowed amfAR to move forward with plans for programmatic expansion in FY2011.

The Foundation’s steady growth in 2010 was accompanied by important programmatic advances. In May 2010, amfAR launched one of the most ambitious and far-reaching research initiatives in its 25-year history. The amfAR Research Consortium on HIV Eradication (ARCHE) announced $1.2 million in grants to four collaborative teams of senior scientists who are actively pursuing a cure for AIDS. amfAR’s commitment to a cure has helped catalyze a surge of interest in cure research, and ARCHE is the centerpiece of its efforts to move this goal forward. TREAT Asia and the MSM Initiative continued to expand their international activities, and amfAR’s public policy office worked tirelessly to promote the needs and protect the rights of people living with HIV and vulnerable to infection.

In 2010, amfAR again met the stringent requirements of governance and financial accountability demanded by the Better Business Bureau’s Wise Giving Alliance and the federal government’s workplace fundraising program, the Combined Federal Campaign, as well as many state employee workplace giving campaigns.

A copy of the complete audited financial statements, prepared in accordance with generally accepted accounting principles for not-for-profit organizations as established by the American Institute of Certified Public Accountants, is available upon request from amfAR at 120 Wall Street, 13th Floor, New York, NY 10005, and can be accessed by visiting www.amfar.org.

Wallace Sheft, C.P.A. Michael J. Klingensmith Treasurer Chair, Finance and Budget Committee

14 Financial Highlights For the year ended September 30, 2010

Public Support and Revenue Public support $ 6,531,572 Special events 9,951,810 Planned giving 2,541,156 Government funding 5,959,900 Investment income and other revenue 1,259,618 Total public support and revenue $ 26,244,056

Expenses Research $ 6,365,071 TREAT Asia 5,480,584 MSM Initiative 1,863,143 Public Policy 1,569,505 Public Information 2,445,829 Total program services $ 17,724,132

Fundraising 4,232,300 Management and general 1,955,217 Total supporting services $ 6,187,517

Total expenses $ 23,911,649

Change in net assets 2,332,407 Net assets, beginning of year 28,233,359

Net assets, end of year $ 30,565,766

Statement of Financial Position

Assets Cash and investments $ 25,033,610 Pledges and receivables 9,331,991 Prepaid expenses and other assets 967,271 Furniture, equipment, and leasehold improvements 471,557 Total Assets $ 35,804,429

Liabilities Accounts payable and accrued expenses $ 1,644,227 Grants and fellowships payable, net 573,764 Deferred support and refundable advances 2,679,898 Other long-term liabilities 340,744 Total liabilities $ 5,238,663

Total net assets 30,565,766

Total liabilities and net assets $ 35,804,429

15 Expenses

Fundraising $ 4,232,300 Management and general 1,955,217 Program 17,724,132

Total $ 23,911,649

Program Expenses

Research $ 6,365,071 TREAT Asia 5,480,584 MSM Initiative 1,863,143 Public Policy 1,569,505 Public Information 2,445,829

Total $ 17,724,132

16 17 Board of Trustees Fiscal Year 2010

Chairman of the Board Treasurer Founding Chairman Kenneth Cole Wallace Sheft, C.P.A. Mathilde Krim, Ph.D. Chairman Partner Adjunct Professor Kenneth Cole Productions Sheft & Co Mailman School of Public Health New York, NY Westbury, NY Columbia University New York, NY Vice Chairman Secretary Patricia J. Matson Diana L. Taylor Senior Vice President, Communications (ret.) Managing Director *Deceased March 23, 2011 ABC, Inc. Wolfensohn & Co. LLC New York, NY New York, NY Vice Chairman Founding International Chairman John C. Simons *Dame Elizabeth Taylor Managing Partner Actress Corporate Fuel Partners LLC Bel Air, CA New York, NY

TRUSTEES Arlen H. Andelson R. Martin Chavez, Ph.D. Edward L. Milstein Andelson Properties Managing Director Co-Chairman Los Angeles, CA Goldman, Sachs & Co. Milstein Brothers Capital Partners New York, NY New York, NY Harry Belafonte President Jane B. Eisner Cindy D. Rachofsky Belafonte Enterprises, Inc. President Philanthropist New York, NY The Eisner Foundation Dallas, TX Bel Air, CA David Bohnett Vincent A. Roberti Chairman Regan Hofmann Chairman and CEO David Bohnett Foundation Editor-in Chief Palisades Media Corp. Beverly Hills, CA POZ Magazine New York, NY New York, NY Zev Braun Alan D. Schwartz President and CEO Michael J. Klingensmith Executive Chairman Braun Entertainment Group, Inc. CEO and Publisher Guggenheim Partners LLC Beverly Hills, CA Minneapolis Star Tribune New York, NY Minneapolis, MN Jonathan S. Canno Mervyn F. Silverman, M.D., M.P.H. New York, NY Michele V. McNeill, Pharm.D. President Chairman Mervyn F. Silverman Associates, Inc. Donald Capoccia McNeill Family Foundation Crockett, CA Managing Principal Long Boat Key, FL BFC Partners Kevin Wendle Brooklyn, NY Richard H. Metzner Entrepreneur Principal New York, NY Metzner-Schneider Associates Dallas, TX

ADJUNCT TRUSTEES TRUSTEES EMERITI David E. Bloom, Ph.D. Arthur J. Ammann, M.D. Chair, Dept. of Population and International Health President, Global Strategies for HIV Prevention Harvard School of Public Health Clinical Professor of Pediatrics Boston, MA University of California, San Francisco Medical Center Mario Stevenson, Ph.D. San Rafael, CA Director, Center for AIDS Research University of Massachusetts Medical School Arnold W. Klein, M.D. Worcester, MA Professor of Medicine/Dermatology University of California, Los Angeles Beverly Hills, C

18 HONORARY TRUSTEES Mouna E. Ayoub Sherry Lansing Pauline Phillips Paris, France Chief Executive Officer/Founder Nationally Syndicated Columnist (ret.) The Sherry Lansing Foundation Los Angeles, CA John F. Breglio, Esq. Los Angeles, CA Paul, Weiss, Rifkind, Wharton & Garrison Leonard Rabinowitz New York, NY Jane F. Nathanson President Psychologist Studio CL Robert L. Burkett Chair, Jane & Marc Nathanson Community Los Angeles, CA The Carmen Group Foundation Washington, D.C. Los Angeles, CA Michael D. Shriver Co-Director, AIDS Policy Research Center Michael Fuchs The Rev. Dr. Randolph Nugent AIDS Research Institute New York, NY General Secretary (ret.) University of California, San Francisco Sandra Hernández, M.D. General Board of Global Ministries San Francisco, CA Chief Executive Officer United Methodist Church The San Francisco Foundation New York, NY San Francisco, CA

IN MEMORIAM Sheldon W. Andelson, Esq. Maxine Mesinger Peter Scott, Esq. Mrs. Albert D. Lasker Natasha Richardson Tom Stoddard Jonathan M. Mann, M.D., M.P.H. Allan Rosenfield, M.D. Joel D. Weisman, D.O.

BOARD COMMITTEES Executive Committee Board Development Committee Finance & Budget Committee Kenneth Cole, Chair Chair (vacant) Michael J. Klingensmith, Chair Michael J. Klingensmith Zev Braun Vincent A. Roberti Mathilde Krim, Ph.D. Jane B. Eisner John C. Simons Patricia J. Matson Mathilde Krim, Ph.D. Wallace Sheft, C.P.A. Patricia J. Matson Fund Development Committee Mervyn Siliverman, M.D., M.P.H. Alan D. Schwartz Vincent A. Roberti, Chair John Simons Jonathan S. Canno Diana L. Taylor Compensation and Organizational Development Edward L. Milstein Committee Audit Committee John C. Simons, Chair Wallace Sheft, C.P.A., Chair Michael J. Klingensmith R. Martin Chavez, Ph.D. Richard H. Metzner John C. Simons

19 Scientific Advisory Committee

Mario Stevenson, Ph.D. (Chair) C. Budd Colby, Ph.D. Gerald Herbert Friedland, M.D. Director, Center for AIDS Research Colby Biomedical Consultants Professor and Director, AIDS Program University of Massachusetts Medical School Department of Internal Medicine Worcester, MA Grant Colfax, M.D. Yale School of Medicine Director of HIV Prevention and Research Sherry Deren, Ph.D. (Co-Chair) San Francisco Department of Public Health Victor Garcia-Martinez, Ph.D. Director, Center for Drug Use and HIV Research Professor of Medicine, School of Medicine Senior Research Scientist Deborah Jean Cotton, M.D., M.P.H. Center for Infectious Diseases New York University College of Nursing Professor of Medicine University of North Carolina, Chapel Hill Department of Medicine Deborah Anderson, Ph.D. Boston University School of Medicine Howard E. Gendelman, M.D. Professor and Director David T. Purtilo Professor of Pathology and Division of Reproductive Biology Bryan Richard Cullen, Ph.D. Microbiology Boston University School of Medicine Professor Department of Pathology and Microbiology Department of Genetics University of Nebraska Medical Center Warren A. Andiman, M.D. Duke University Medical Center Professor of Pediatrics, Epidemiology and Public Stephen P. Goff, Ph.D. Health Susanna Cunningham-Rundles, Ph.D. Higgins Professor of Microbiology & Immunology Department of Pediatrics Professor of Immunology and Biochemistry & Molecular Biophysics Yale University School of Medicine Department of Pediatrics Howard Hughes Medical Institute Cornell University Medical College Columbia University Jose Arturo Bauermeister, M.P.H., Ph.D. Research Assistant Professor Richard Thomas D’Aquila, M.D. Nancy L. Haigwood, Ph.D. Department of Health Behavior and Health Addison B. Scoville Professor of Medicine Director and Senior Scientist Education Department of Medicine Division of Pathobiology & Immunology University of Michigan Vanderbilt University School of Medicine Oregon National Primate Research Center Michael Belshan, Ph.D. Ronald C. Desrosiers, Ph.D. Dean Hamer, Ph.D. Assistant Professor Professor of Microbiology and Molecular Genetics Senior Investigator and Head Department of Medical Microbiology and Harvard Medical School Gene Structure and Regulation Section Immunology Roger Detels, M.D., M.S. National Cancer Institute, National Institutes of Creighton University Professor of Epidemiology Health Jason Brenchley, Ph.D. School of Public Health Daria Hazuda, Ph.D. Tenure-Track Investigator University of California, Los Angeles Vice President of Virus and Cell Biology Laboratory of Molecular Microbiology Carl W. Dieffenbach, Ph.D. Department of Antiretroviral Research, Molecular National Institute of Allergy and Infectious Director, Basic Sciences Program Endocrinology, Virus and Cell Support, and Diseases, National Institutes of Health Division of AIDS Medicinal Chemistry Merck Research Laboratories Dennis R. Burton, Ph.D. National Institute of Allergy and Infectious Professor Diseases, National Institutes of Health Charles H. Hinkin, Ph.D. Department of Immunology Daniel C. Douek, M.D., Ph.D. Associate Professor The Scripps Research Institute Chief, Human Immunology Section Department of Psychiatry and Biobehavioral Vaccine Research Center Science Salvatore T. Butera, D.V.M., Ph.D. University of California School of Medicine Chief National Institute of Allergy and Infectious Virology Section Diseases, National Institutes of Health David Ho, M.D. Centers for Disease Control and Prevention D. Peter Drotman, M.D., M.P.H. Scientific Director, Chief Executive Officer Editor-in-Chief Irene Diamond Professor Edward Campbell, Ph.D. Aaron Diamond AIDS Research Center Assistant Professor Emerging Infectious Diseases School of Medicine Centers for Disease Control and Prevention Thomas J. Hope, Ph.D. Loyola University Chicago Anke A. Ehrhardt, Ph.D. Professor Department of Cell and Molecular Biology Alex Carballo-Dieguez, Ph.D. Director and Professor Department of Psychiatry Northwestern University Feinberg School of Research Scientist and Professor of Clinical Medicine Psychology Columbia University Department of Psychology Homayoon Farzadegan, Ph.D. Keith J. Horvath, Ph.D. Columbia University Professor Assistant Professor Department of Epidemiology School of Public Health Larry Williams Chang, M.D., Ph.D. University of Minnesota Department of Medicine Johns Hopkins University Johns Hopkins University Dianne M. Finkelstein, Ph.D. Shiu-Lok Hu, Ph.D. Professor David B. Clifford, M.D. Director of Biostatistics Cancer Center Biostatistics School of Pharmacy Professor University of Washington Department of Neurology Massachusetts General Hospital and Harvard Washington University School of Medicine Medical School Kuan Teh Jeang, Ph.D. Alan Frankel, Ph.D. Chief Eric Cohen, Ph.D. Medical Virology Section Research Unit Director Professor Department of Biochemistry and Biophysics National Institute for Allergy and Infectious Department of Human Retrovirology Diseases, National Institutes of Health Institut de recherches cliniques de Montréal University of California, San Francisco

20 Fatah Kashanchi, Ph.D. Manuel Llano, M.D., Ph.D. Tristram G. Parslow, M.D., Ph.D. Professor Assistant Professor William Patterson Timmie Professor and Chair Department of Biochemistry and Molecular Department of Biological Sciences Department of Pathology and Laboratory Medicine Biology University of Texas, El Paso Emory University School of Medicine George Washington University Medical Center Shan Lu, Ph.D., M.D. Matija Peterlin, M.D. Ronald C. Kennedy, Ph.D. Professor Professor Chairman and Professor Department of Immunology and Virology Department of Medicine Department of Microbiology and Immunology University of Massachusetts Medical School University of California, San Francisco Texas Tech University Health Sciences Center Hinh Ly, Ph.D. Lynn Pulliam, Ph.D. Vineet KewalRamani, Ph.D. Assistant Professor Professor in Residence Chief, Model Development Section Pathology & Laboratory Medicine Department Chief of Microbiology HIV Drug Resistance Program Emory University School of Medicine Department of Laboratory Medicine and Medicine National Cancer Institute, National Institutes of University of California, San Francisco/Veterans Health H. Kim Lyerly, M.D. Affairs Medical Center Professor in Surgery, Immunology, Pathology Richard Kornbluth, M.D., Ph.D. Duke Comprehensive Cancer Institute Han-Zhu Qian, M.D., Ph.D. Associate Professor of Medicine Duke University Medical Center Assistant Professor of Medicine Department of Medicine Vanderbilt Institute for Global Health University of California, San Diego Harmit Malik, Ph.D. Vanderbilt University Principal Investigator Richard A. Koup, M.D. Division of Basic Sciences Lee Ratner, M.D., Ph.D. Chief, Immunology Laboratory Fred Hutchinson Cancer Research Center Professor Vaccine Research Center Department of Medicine National Institute of Allergy and Infectious David M. Margolis, M.D. Washington University School of Medicine Diseases, National Institutes of Health Professor of Microbiology, Medicine and Public Health Scott Rhodes, Ph.D., M.P.H, C.H.E.S. Priti Kumar, Ph.D. School of Medicine Associate Professor Assistant Professor University of North Carolina, Chapel Hill Department of Social Sciences and Health Policy Yale School of Medicine Wake Forest University School of Medicine Martin H. Markowitz, M.D. Nathaniel R. Landau, Ph.D. Staff Investigator Andrew Rice, Ph.D. Professor Aaron Diamond AIDS Research Center Professor Department of Microbiology Department of Molecular Virology and New York University School of Medicine Kenneth Hugh Mayer, M.D. Microbiology Chief, Division of Infectious Diseases Baylor College of Medicine Alan L. Landay, Ph.D. Immunology Center Professor and Associate Chairman Miriam Hospital Cornelis A. Rietmeijer, M.D., Ph.D. Department of Immunology and Microbiology Professor of Medicine and Community Health Director, STD Control Program Rush-Presbyterian-St.Luke’s Medical Center Brown University Denver Public Health Department Jeffrey Laurence, M.D. Joseph M. McCune, M.D., Ph.D. Melissa Robbiani, Ph.D. Professor of Medicine Professor of Medicine Sr. Scientist and Director of Biomedical HIV Director, Laboratory for AIDS Virus Research Division of Experimental Medicine Research Weill Medical College of Cornell University University of California, San Francisco Center for Biomedical Research Population Council Michael Lederman, M.D. Donna Mildvan, M.D. Professor of Medicine, Director Chief Ruth M. Ruprecht, M.D., Ph.D. Center for AIDS Research Department of Medicine Professor of Medicine Case Western Reserve University Beth Israel Medical Center Department of Cancer Immunology and AIDS Dana-Farber Cancer Institute and Harvard Medical Tun-Hou Lee, D.Sc. Jay A. Nelson, Ph.D. School Professor of Virology Professor and Director Department of Immunology and Infectious Division of Pathobiology and Immunology Frederick A. Schmitt, Ph.D. Diseases Oregon Health Sciences University Associate Professor Harvard School of Public Health Departments of Neurology, Psychiatry & Nancy Padian, M.P.H., Ph.D. Psychology Michael J. Leibowitz, M.D., Ph.D. Distinguished Fellow University of Kentucky Medical Center Professor Women’s Global Health Imperative Department of Molecular Genetics and RTI International Gerald Schochetman, Ph.D. Microbiology Director, AIDS Research and Retrovirus Discovery University of Medicine and Dentistry of New Savita Pahwa, M.D. Abbott Laboratories Jersey-Robert Wood Johnson Medical School Director Microbiology and Immunology Robert Turner Schooley, M.D. Robert J. Levine, M.D. Leonard M. Miller School of Medicine Academic Vice Chair Professor of Medicine University of Miami Professor and Head Center for Interdisciplinary Research on AIDS Department of Medicine/Division of Infectious Yale University Deborah Palliser, Ph.D. Diseases Assistant Professor University of California, San Diego Judy Lieberman, M.D., Ph.D. Department of Microbiology & Immunology Senior Investigator Albert Einstein College of Medicine Immune Disease Institute Professor of Pediatrics Harvard Medical School

21 Ann M. Sheehy, Ph.D. Lishan Su, Ph.D. Steven S. Witkin, Ph.D. Assistant Professor Associate Professor Professor and Director Biology Department Department of Microbiology and Immunology Department of Obstetrics and Gynecology College of the Holy Cross University of North Carolina-Chapel Hill Weill Medical College of Cornell University Frederick P. Siegal, M.D. Ernest F. Terwilliger, Ph.D. Peter R. Wolfe, M.D. Chief, Section of HIV Medicine and Medical Assistant Professor Los Angeles, California Director Beth Israel Deaconess Medical Center Department of Medicine Richard T. Wyatt, Ph.D. Saint Vincent’s Hospital and Medical Center Barbara Visscher, M.D., Dr.P.H. Professor of Immunology Professor of Epidemiology International AIDS Vaccine Initiative Center for Gail Skowron, M.D. Department of Epidemiology Neutralizing Antibodies Associate Professor of Medicine University of California, Los Angeles Scripps Research Institute Department of Medicine, Division of Infectious Diseases David Vlahov, Ph.D. Xiao-Fang Yu, M.D., D.Sc. Roger Williams Medical Center Director Professor Center for Urban Epidemiologic Studies Department of Molecular Microbiology and Leonidas Stamatatos, Ph.D. New York Academy of Medicine Immunology Full Member and Director of Viral Vaccines Bloomberg School of Public Health Program David J. Volsky, Ph.D. Johns Hopkins University Seattle Biomedical Research Institute Professor and Director Department of Pathology and Medicine Klaus Strebel, Ph.D. St. Luke’s-Roosevelt Hospital Center and Chief, Viral Biochemistry Section Columbia University Laboratory of Molecular Microbiology National Institute of Allergy and Infectious Mark A. Wainberg, Ph.D. Diseases, National Institutes of Health Professor and Director McGill AIDS Centre McGill University

Program Advisory Council

Mervyn Silverman, M.D., M.P.H. (Chairman) Daria J. Hazuda, Ph.D. President Vice President Mervyn F. Silverman Associates, Inc. Worldwide Franchise Discovery Head for Antivirals Merck & Company, Inc. David Bloom, Ph.D. (Co-chairman) Chair, Department of Global Health and Population Kenneth H. Mayer, M.D. Harvard School of Public Health Professor of Medicine and Community Health Brown University, Alpert Medical School Mario Stevenson, Ph.D. (Co-chairman) Infectious Diseases Division Professor of Medicine, Chief, Division of Infectious The Miriam Hospital Diseases Medical Research Director University of Miami Fenway Health Leonard M. Miller School of Medicine Jeffrey L. Sturchio, Ph.D. Tim Brown, Ph.D. President and Chief Executive Officer Senior Fellow The Global Health Council The East-West Center

Management Group

Kevin Robert Frost Rowena Johnston, Ph.D. Chief Executive Officer Vice President and Director, Research Anthony Ancona Jeffrey Laurence, M.D. Vice President and Director, Human Resources Senior Scientific Consultant for Programs Susan J. Blumenthal, M.D., M.P.A. John F. Logan, Ph.D., J.D. Senior Policy and Medical Advisor Vice President and General Counsel Gregory Boroff, C.A.E., C.F.R.E. AnnMari Shannahan Vice President and Director, Development Vice President, Public Information Chris Collins, M.P.P. Annette Sohn, M.D. Vice President and Director, Public Policy Vice President and Director, TREAT Asia Bradley Jensen Chief Financial Officer

22 23 amfAR, The Foundation for AIDS Research

NEW YORK 120 Wall Street, 13th Floor New York, NY 10005-3908 (212) 806-1600 (tel) (212) 806-1601 (fax)

WASHINGTON, D.C. 1150 17th Street, NW Suite 406 Washington, DC 20036-4622 (202) 331-8600 (tel) (202) 331-8606 (fax)

BANGKOK, THAILAND TREAT Asia Exchange Tower 388 Sukhumvit Road, Suite 2104 Klongtoey, Bangkok 10110 Thailand +66 (0)2 663 7561 (phone) +66 (0)2 663 7562 (fax) www.amfar.org